On October 14, 2025, Fate Therapeutics announced the appointment of Kamal Adawi, M.S., M.B.A., as its new Chief Financial Officer, effective October 20, 2025.
Adawi brings more than 20 years of financial leadership experience and will oversee the company’s financial strategy, reporting, and capital management as it advances its iPSC‑derived immunotherapy pipeline.
The appointment reflects Fate’s ongoing effort to strengthen its executive leadership team in support of its clinical and commercial objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.